Skip to main content
MEDS
NASDAQ Trade & Services

DataMEDS AI Swings to $10.5M Q3 Profit on Debt Extinguishment; Revenue Up 50% Sequentially

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.75
Mkt Cap
$3.342M
52W Low
$0.553
52W High
$35.5
52W Position info
36% above low
Off High info
98% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MEDS sits 36% above its 52-week low of $0.553.

Summary

DataMEDS AI reported Q3 2026 revenue of $2.7 million, up 50% sequentially, and net income of $10.5 million driven almost entirely by a $19.1 million debt-extinguishment gain. The company also said it regained full Nasdaq compliance on October 19, 2026.


Key Events · Earnings and Guidance · MEDS

  • Q3 Revenue Up 50% Sequentially

    Revenue was $2.7 million versus $1.8 million in Q2 2026, driven by Corexa Pharmacy drug dispensing, though still below the $3.0 million reported in Q3 2025.

  • Profit Is a Debt-Extinguishment Gain

    Net income of $10.536 million included a $19.06 million gain on extinguishment of debt; the company actually ran a $3.37 million operating loss in the quarter.

  • Nasdaq Compliance Restored

    The company said it regained full compliance with Nasdaq listing standards, including the net equity requirement, on October 19, 2026.

  • Equity Turns Positive

    Stockholders' equity was $171,695 at September 30, 2026 versus a $12.45 million deficit at December 31, 2025, with cash of $476,598 against $37.9 million of current liabilities.


Analysis · MEDS · Trade & Services

The headline profit is accounting-driven, not operational: a $19.06 million gain on extinguishment of debt turned a $3.37 million operating loss into $10.54 million of net income. More important is the balance sheet. Stockholders' equity flipped from a $12.45 million deficit at year-end 2025 to $171,695 positive at September 30, 2026, and the company says it regained full Nasdaq compliance on October 19, 2026, removing the delisting risk flagged in the Q2 10-Q. Revenue of $2.7 million rose 50% sequentially but is still down from $3.0 million a year earlier, and cash of $476,598 against $37.9 million of current liabilities leaves little cushion. The HMO MOU covering 25,000+ members is non-binding, with definitive agreements only expected in Q4 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $0.75 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.55 to $35.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $0.7001 info
Change: -$0.1794 (-20%) info
Market Cap: $3.342M info
MEDS
Nov 10, 2026, 4:30 PM EST
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $0.9215
Real-time Price: $0.7001 info
Change: -$0.2214 (-24%) info
Market Cap: $3.342M info
MEDS
Nov 05, 2026, 6:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $0.7001 info
Change: -$0.8099 (-54%) info
Market Cap: $3.342M info
MEDS
Nov 03, 2026, 6:18 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $0.7001 info
Change: -$0.9999 (-59%) info
Market Cap: $3.342M info
MEDS
Oct 26, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.14
Real-time Price: $0.7001 info
Change: -$1.44 (-67%) info
Market Cap: $3.342M info